PDCD1 and neoplasm: Both denosumab (anti‐RANKL) and anti‐PD‐1/PD‐L1 mAbs result in some systemic toxicities as monotherapies.28, 29 However, whether the more tumor‐selective biodistribution of anti‐RANKL/PD‐1 BsAb mitigates any toxicities resulting from either monotherapy or combination of anti‐RANKL plus anti‐PD‐1/PD‐L1 antibodies remains to be tested.